论文部分内容阅读
目的:在新西兰高加索人种中对使用硫唑嘌呤(azathioprine,AZA)、甲氨蝶呤(methotrexate,MTX)治疗没有免疫抑制的中到重度炎症性肠病(inflammatoryboweldisease,IBD)患者进行成本-效果分析,并且分析了对AZA新陈代谢能力差的患者进行前瞻性基因型或者表型检测是否具有成本有效性
OBJECTIVE: To evaluate the cost-effectiveness of New Zealand Caucasians in the treatment of patients with moderate-to-severe inflammatory bowel disease (IBD) without immunosuppression using azathioprine (AZA) and methotrexate (MTX) Analysis and analyzed whether cost-effectiveness of prospective genotypic or phenotypic testing of patients with poor metabolizable AZA